BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Enache D, Nikkheslat N, Fathalla D, Morgan BP, Lewis S, Drake R, Deakin B, Walters J, Lawrie SM, Egerton A, MacCabe JH, Mondelli V. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophr Res 2021;230:1-8. [PMID: 33667853 DOI: 10.1016/j.schres.2020.12.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Shnayder NA, Khasanova AK, Strelnik AI, Al-zamil M, Otmakhov AP, Neznanov NG, Shipulin GA, Petrova MM, Garganeeva NP, Nasyrova RF. Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia. IJMS 2022;23:11324. [DOI: 10.3390/ijms231911324] [Reference Citation Analysis]
2 Liu C, Liu C, Hsieh M, Hwang T, Lin Y, Chien Y, Hwu H. The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis. Psychiatry Research 2022. [DOI: 10.1016/j.psychres.2022.114775] [Reference Citation Analysis]
3 Benros ME. High-quality large-scale longitudinal studies with detailed multimodal immunological phenotyping are warranted to disentangle the involvement of the immune system in psychosis. Acta Psychiatr Scand 2022;146:3-5. [PMID: 35714064 DOI: 10.1111/acps.13458] [Reference Citation Analysis]
4 Suhas S, Mehta UM. A redux of schizophrenia research in 2021. Schizophr Res 2022:S0920-9964(22)00130-X. [PMID: 35300898 DOI: 10.1016/j.schres.2022.03.003] [Reference Citation Analysis]
5 Yan J, Chen Y, Ju P, Gao J, Zhang L, Li J, Wang K, Zhang J, Li C, Xia Q, Zhu C, Zhang X. Network Association of Biochemical and Inflammatory Abnormalities With Psychiatric Symptoms in First-Episode Schizophrenia Patients. Front Psychiatry 2022;13:834539. [PMID: 35273531 DOI: 10.3389/fpsyt.2022.834539] [Reference Citation Analysis]
6 Li J, Yoshikawa A, Alliey-rodriguez N, Meltzer HY. Schizophrenia risk loci from xMHC region were associated with antipsychotic response in chronic schizophrenic patients with persistent positive symptom. Transl Psychiatry 2022;12. [DOI: 10.1038/s41398-022-01854-9] [Reference Citation Analysis]
7 Li M, Qiu Y, Zhang J, Zhang Y, Liu Y, Zhao Y, Jia Q, Fan X, Li J. Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 35037116 DOI: 10.1007/s00406-021-01359-4] [Reference Citation Analysis]
8 Mohd Asyraf AJ, Nour El Huda AR, Hanisah MN, Norsidah KZ, Norlelawati AT. Relationship of selective complement markers with schizophrenia. J Neuroimmunol 2021;363:577793. [PMID: 34990981 DOI: 10.1016/j.jneuroim.2021.577793] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mondelli V, Cattaneo A, Nikkheslat N, Souza L, Walsh A, Zajkowska Z, Zonca V, Marizzoni M, Fisher HL, Kohrt BA, Kieling C, Di Meglio P. Exploring the role of immune pathways in the risk and development of depression in adolescence: Research protocol of the IDEA-FLAME study. Brain Behav Immun Health 2021;18:100396. [PMID: 34927102 DOI: 10.1016/j.bbih.2021.100396] [Reference Citation Analysis]
10 Petralia MC, Ciurleo R, Bramanti A, Bramanti P, Saraceno A, Mangano K, Quattropani MC, Nicoletti F, Fagone P. Transcriptomic Data Analysis Reveals a Down-Expression of Galectin-8 in Schizophrenia Hippocampus. Brain Sci 2021;11:973. [PMID: 34439592 DOI: 10.3390/brainsci11080973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]